Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.755 USD | -7.14% | -13.55% | -88.08% |
05-09 | Transcript : Amylyx Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
05-09 | Amylyx Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Business Summary
Number of employees: 384
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Relyvrio (Sodium Phenylbutyrate and Taurursodiol)
100.0
%
| 22 | 100.0 % | 381 | 100.0 % | +1,612.94% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 22 | 100.0 % | 381 | 100.0 % | +1,612.94% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Justin Klee
FOU | Founder | 34 | 12-12-31 |
Josh Cohen
FOU | Founder | 33 | 12-12-31 |
Jim Frates
DFI | Director of Finance/CFO | 56 | 20-12-31 |
Chief Tech/Sci/R&D Officer | 71 | 11-27 | |
Lindsey Allen
IRC | Investor Relations Contact | - | - |
Gina Mazzariello
LAW | General Counsel | 53 | 22-02-22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
George Milne
CHM | Chairman | 80 | 14-12-31 |
Kari Firestone
BRD | Director/Board Member | - | 23-03-15 |
Paul R. Fonteyne
BRD | Director/Board Member | 63 | 21-03-28 |
Daphne Quimi
BRD | Director/Board Member | 58 | 21-06-28 |
Josh Cohen
FOU | Founder | 33 | 12-12-31 |
Justin Klee
FOU | Founder | 34 | 12-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 68,005,749 | 56,458,350 ( 83.02 %) | 0 | 83.02 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-88.08% | 119M | |
-2.61% | 89.08B | |
+3.55% | 40.9B | |
-14.40% | 32.25B | |
+55.89% | 25.14B | |
-15.96% | 15.39B | |
-15.50% | 11.91B | |
-41.29% | 11.89B | |
-11.75% | 11.64B | |
+7.87% | 9.03B |
- Stock Market
- Equities
- AMLX Stock
- Company Amylyx Pharmaceuticals, Inc.